ENTOD Pharma gets CDSCO approval for eye drops to treat presbyopia
April 22, 2024
Source: drugdu
135
ENTOD Pharmaceuticals received approval from CDSCO for PresVu, a treatment for presbyopia, by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). PresVu is a eye drop in India designed to alleviate the need for reading glasses among individuals grappling with presbyopia.
Presbyopia, characterised by blurred near vision due to the decreased flexibility of the eye’s natural lens, primarily impacts individuals aged 40 and above. PresVu offers swift relief and temporary correction of vision problems associated with presbyopia. PresVu eye drops adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use.
The company completed development of these eye drops in late 2022 after which it was subjected to clinical testing in India. Reportedly, Phase 3 clinical trials carried out in India and the US have demonstrated PresVu’s efficacy in enhancing close-up vision within minutes of application, with effects lasting up to six hours. This formulation holds promise for individuals aged 40 to 55 with mild to intermediate presbyopia.
https://www.pharma.in/entod-pharma-gets-cdsco-approval-for-eye-drops-to-treat-presbyopia/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Baique Ling’s products involved have no violations, and the official flag’s daily sales have increased by 500% November 23, 2024
- 750 million license in, Chinese pharmaceutical companies make money overseas and spend overseas November 23, 2024
- Rocket material leader, 400 million bet on medical imaging November 23, 2024
- Simeglutide Weight Loss Edition Officially Enters the Chinese Market November 23, 2024
- What signal did the National Medical Insurance Administration send out when it held a meeting with more than 40 leading enterprises? November 23, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
